{
  "version": "1.0",
  "updated_at": "2026-01-12T10:00:00.000000",
  "count": 6,
  "hypotheses": [
    {
      "gene": "VCP",
      "protein": "Valosin-containing protein (p97)",
      "uniprot_id": "P55072",
      "variants": [
        {
          "id": "chr9_35056064_G_A",
          "chrom": "chr9",
          "pos": 35056064,
          "ref": "G",
          "alt": "A",
          "consequence": "missense_variant",
          "impact": "HIGH",
          "hgvs_p": "p.Arg155His",
          "clinical_significance": "Pathogenic"
        }
      ],
      "variant_count": 1,
      "rationale": "VCP (p97) is an AAA+ ATPase critical for protein quality control. Mutations cause IBMPFD (Inclusion Body Myopathy with Paget disease and Frontotemporal Dementia). VCP is a validated drug target with inhibitors in development including CB-5083. The protein plays key roles in ERAD, autophagy, and DNA damage response - dysfunction leads to protein aggregation and neurodegeneration.",
      "therapeutic_area": "Neurodegeneration",
      "mechanism": "AAA+ ATPase inhibition to modulate protein homeostasis",
      "confidence": "high",
      "priority": 5,
      "id": "TH-20260112-VCP-FTD",
      "created_at": "2026-01-12T10:00:00.000000",
      "updated_at": "2026-01-12T10:00:00.000000",
      "source_query": "What genes are associated with frontotemporal dementia?",
      "notes": "Primary target for FTD drug discovery demo. Reference compound: CB-5083 (VCP/p97 inhibitor).",
      "status": "validated",
      "pdb_ids": [
        "5FTK",
        "5FTJ",
        "5FTI"
      ]
    },
    {
      "gene": "EGFR",
      "protein": "Epidermal growth factor receptor",
      "uniprot_id": "P00533",
      "variants": [],
      "variant_count": 0,
      "rationale": "Key oncology target with known druggable kinase domain. Multiple approved inhibitors (erlotinib, gefitinib, osimertinib).",
      "therapeutic_area": "Oncology",
      "mechanism": "Tyrosine kinase inhibition",
      "confidence": "high",
      "priority": 5,
      "id": "TH-20260109183212-EGFR",
      "created_at": "2026-01-09T18:32:12.253620",
      "updated_at": "2026-01-12T10:00:00.000000",
      "source_query": null,
      "notes": "",
      "status": "validated",
      "pdb_ids": [
        "7SYE",
        "1M17"
      ]
    },
    {
      "gene": "BRAF",
      "protein": "B-Raf proto-oncogene",
      "uniprot_id": "P15056",
      "variants": [],
      "variant_count": 0,
      "rationale": "V600E mutation is highly druggable with approved inhibitors (vemurafenib, dabrafenib).",
      "therapeutic_area": "Oncology",
      "mechanism": "Kinase inhibition",
      "confidence": "high",
      "priority": 5,
      "id": "TH-20260109183212-BRAF",
      "created_at": "2026-01-09T18:32:12.255612",
      "updated_at": "2026-01-12T10:00:00.000000",
      "source_query": null,
      "notes": "",
      "status": "validated",
      "pdb_ids": [
        "6P3D",
        "4MNE"
      ]
    },
    {
      "gene": "KRAS",
      "protein": "GTPase KRas",
      "uniprot_id": "P01116",
      "variants": [],
      "variant_count": 0,
      "rationale": "G12C mutation targetable with covalent inhibitors (sotorasib, adagrasib). Previously considered undruggable.",
      "therapeutic_area": "Oncology",
      "mechanism": "Covalent GTPase inhibition",
      "confidence": "high",
      "priority": 4,
      "id": "TH-20260109183212-KRAS",
      "created_at": "2026-01-09T18:32:12.256167",
      "updated_at": "2026-01-12T10:00:00.000000",
      "source_query": null,
      "notes": "",
      "status": "validated",
      "pdb_ids": [
        "6OIM"
      ]
    },
    {
      "gene": "PIK3CA",
      "protein": "PI3K catalytic subunit alpha",
      "uniprot_id": "P42336",
      "variants": [],
      "variant_count": 0,
      "rationale": "PI3K pathway target with approved inhibitor alpelisib for breast cancer.",
      "therapeutic_area": "Oncology",
      "mechanism": "Lipid kinase inhibition",
      "confidence": "medium",
      "priority": 4,
      "id": "TH-20260109183212-PIK3CA",
      "created_at": "2026-01-09T18:32:12.255893",
      "updated_at": "2026-01-12T10:00:00.000000",
      "source_query": null,
      "notes": "",
      "status": "hypothesis",
      "pdb_ids": [
        "4JPS"
      ]
    },
    {
      "gene": "JAK2",
      "protein": "Tyrosine-protein kinase JAK2",
      "uniprot_id": "O60674",
      "variants": [],
      "variant_count": 0,
      "rationale": "V617F mutation driver of myeloproliferative neoplasms. Multiple approved inhibitors (ruxolitinib, fedratinib).",
      "therapeutic_area": "Hematology",
      "mechanism": "Tyrosine kinase inhibition",
      "confidence": "medium",
      "priority": 4,
      "id": "TH-20260109183212-JAK2",
      "created_at": "2026-01-09T18:32:12.256430",
      "updated_at": "2026-01-12T10:00:00.000000",
      "source_query": null,
      "notes": "",
      "status": "hypothesis",
      "pdb_ids": [
        "4IVA"
      ]
    }
  ]
}
